Showing results (181-190 of 221) with videos related to
Sort By:
Pageof 23
Gastroenterology|July 17, 2007
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006Michael Clark, Jean-Frederic Colombel, Brian C Feagan, et al.Inflammatory Bowel Diseases|April 13, 2011
Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studiesWalter Reinisch, William J Sandborn, Paul Rutgeerts, et al.Inflammatory Bowel Diseases|May 2, 2009
Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximabWaqqas Afif, Jonathan A Leighton, Stephen B Hanauer, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 22, 2021
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI TrialWilliam J Sandborn, Rory Rebuck, Yuhua Wang, et al.Proceedings of the National Academy of Sciences of the United States of America|May 4, 2026
Eosinophil-derived COX-2 protects against experimental colitis through the PGE2-IL-22 axisYang Yang, Constance L Atkins, Yuanyuan Fan, et al.Gastroenterology|July 5, 2011
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitisJean Frédéric Colombel, Paul Rutgeerts, Walter Reinisch, et al.Inflammatory Bowel Diseases|December 22, 2023
The Disease Severity Index for Inflammatory Bowel Disease Is a Valid Instrument that Predicts Complicated DiseaseAkhilesh Swaminathan, James M Fulforth, Chris M Frampton, et al.Gastroenterology|July 15, 2009
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximabWilliam J Sandborn, Paul Rutgeerts, Brian G Feagan, et al.Therapeutic Advances in Gastroenterology|October 13, 2025
Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysisMarc Ferrante, Laurent Peyrin-Biroulet, Perttu Arkkila, et al.Journal of Crohn'S & Colitis|September 22, 2023
Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohn's Disease Patients: A Prospective Open-label StudyGeert D'Haens, Michael Eberhardson, Zeljko Cabrijan, et al.Pageof 23